Clinical Trial Update: Prasugrel Monotherapy Reduced Dose in Acute and Chronic Coronary Syndrome Patients After Percutaneous Coronary Intervention (PROMOTE) [Phase 4]

View source ↗

Summary

PROMOTE is a Phase 4 clinical trial evaluating reduced-dose prasugrel monotherapy in patients with acute and chronic coronary syndrome after PCI. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome

Drugs mentioned

• PRASUGREL (prasugrel)

Snippet

Sponsor: J.P.S Henriques | Conditions: Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI) | Phase 4 | Status: RECRUITING